Showing 4451-4460 of 5998 results for "".
- AccuTec Blades: New Catalog Launches AccuThrive Brandhttps://practicaldermatology.com/news/accutec-blades-new-catalog-launches-accuthrive-brand/2460719/Introducing the newAccuThrive® medical brand, AccuTec Blades® Inc. has published its 2021 histology catalog. The 2021 AccuThrive blades portfolio highlights
- Launching from Nutrafol: New Pro-Strength Boostershttps://practicaldermatology.com/news/launching-from-nutrafol-new-pro-strength-boosters/2460713/New professional-strength boosters from Nutrafol extend the popular nutraceutical line, providing physicians the opportunity to individualize recommendations for each patient’s specific hair health needs. Hairbiotic MD is a professional-strength
- Baricitinib Performs Well in Phase 3 AA Trialhttps://practicaldermatology.com/news/baricitinib-performs-well-in-phase-3-aa-trial/2460709/Eli Lilly and Company and Incyte’s Baricitinib is the first JAK inhibitor to demonstrate hair regrowth in a Phase 3 alopecia areata (AA) trial. Patients with severe alopecia areata who took baricitinib 2-mg or 4-mg once daily showed a statistically significant improvemen
- Vyne Therapeutics to Move Forward with Topical Tofacitinib/Fingolimod Gel for ADhttps://practicaldermatology.com/news/vyne-therapeutics-to-move-forward-with-topical-tofacitinibfingolimod-gel-for-ad/2460707/Vyne Therapeutics Inc. plans to move forward on development of its fixed combination of pan-JAK inhibitor tofacitinib and sphingosine 1-phosphate receptor modulator fingolimod in a topical gel for mild-to-moderate atopic dermatitis. A phase 2a proof of concept study for FMX114 is planned to start
- New Research Highlights Global Challenge of Leprosyhttps://practicaldermatology.com/news/new-research-highlights-global-challenge-of-leprosy/2460706/The global problem of leprosy may be bigger than recognized, new research suggests. In fact, 40 million individuals around the world require preventive treatment in order to reduce the incidence of leprosy or Hansen’s Disease by 90% in 22 years. The new research by
- Galderma and Aklief Unveil "Me Being Me" Campaign, Survey Results on Acne Zoom Burdenhttps://practicaldermatology.com/news/galderma-and-aklief-unveil-me-being-me-campaign-survey-results-on-acne-zoom-burden/2460703/Galderma Laboratories, L.P. and Aklief (trifarotene) Cream, 0.005% are launching Me Being Me, a new consumer campaign that was crafted in response to today’s increasingly digital-focused world. The campaign is designed to inspire those living with acne to feel confident
- AbbVie, Evolus Agree to Settlementhttps://practicaldermatology.com/news/abbvie-evolus-agree-to-settlement/2460697/AbbVie, Evolus, and Medytox have agreed to a new settlement to fully resolve all outstanding litigation, including the US International Trade Commission (ITC) case regarding the sale of Jeuveau®, between the companies. A California court case filed by Medytox against Evolus will be
- Breaking Business News: Evolus' Jeuveau Can Stay on U.S. Market For Nowhttps://practicaldermatology.com/news/breaking-business-news-evolus-jeuveau-can-stay-on-us-market-for-now/2460690/Evolus Inc. can remain for sale in the U.S. temporarily while an appeals court re-considers an import ban won by AbbVie Inc.’s Allergan that was slated to go into effect on Feb. 16, 2021, according to
- Registration Open for Biologic & Small Molecule NP/PA CME Virtual Bootcamphttps://practicaldermatology.com/news/registration-open-for-biologic-small-molecule-nppa-cme-virtual-bootcamp/2460689/The Biologic & Small Molecule NP/PA CME Virtual Bootcamp is coming Saturday, March 6. Topics for the program, presented by the Dermatology Education Foundation, include therapeutic updates in atopic dermatitis and psoriasis, patient initiation for biologics and small molec
- COVID-19, the Stock Market, and Dermatologyhttps://practicaldermatology.com/news/covid-19-the-stock-market-and-dermatology/2460688/By Amylee Martin, BS, Akshitha Thatiparthi, BS, Jeffrey Liu, BS, Jashin J. Wu, MD Novel coronavirus, COVID-19, is not only a major public health threat but has also impacted the economy. Due to the pandemic, experts predict a 0.5% decrease in t